Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: TNF is a clinical-stage pharmaceutical company focused on extending healthy lifespan through two therapeutic platforms: Isomyosamine (an oral TNF-α inhibitor for autoimmune diseases and sarcopenia) and Supera-CBD (a synthetic CBD analog for epilepsy, pain, and anxiety). The company has no commercial product revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(23,359,334) | $(3,999,950) |
| Net Loss Attributable to Common Shareholders | $(27,161,219) | $(8,218,163) |
| Cash and Cash Equivalents (Year End) | $173,154 | $2,681,010 |
| Marketable Securities (Year End) | $8,345,082 | $2,242,106 |
| Total Current Assets | $9,411,966 | $5,816,342 |
| Working Capital | $2,710,626 | $828,253 |
| Accumulated Deficit | $(129,138,286) | $(101,977,067) |
| Operating Cash Flow | $(8,976,347) | $(12,980,625) |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately 484% year-over-year, driven primarily by non-cash losses related to the issuance of Series F-1 and Series G Preferred Stock ($8.8M combined) and changes in the fair value of warrant liabilities ($4.4M loss).
- Operating Expense Reduction: Total operating expenses decreased by 40.6% to $10.2M from $17.1M. Research and Development expenses dropped 56.3% to $3.4M, and General and Administrative expenses fell 23.5% to $4.2M, reflecting workforce reductions and cost-cutting measures.
- Capital Structure Changes: The company completed private placements of Series F-1 and Series G Convertible Preferred Stock in May 2024, raising approximately $14M in net proceeds. These financings included full-ratchet anti-dilution provisions, leading to significant non-cash losses upon issuance.
- Corporate Actions: The company changed its name from MyMD Pharmaceuticals, Inc. to TNF Pharmaceuticals, Inc. in July 2024 and changed its ticker symbol to "TNFA". A 1-for-30 reverse stock split was effected in February 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Pipeline: Management plans to launch a Phase 2b clinical trial for Isomyosamine in sarcopenia in Q1 2025. A collaborative, fully funded study with Renova Health regarding GLP-1-induced sarcopenia is also planned.
- Liquidity Strategy: The company raised capital in 2024 to extend its runway. Management believes current resources are sufficient to fund operations for the next 12 months, though this is contingent on successful execution of financing strategies.
Material Risks and Contingencies
- Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient liquidity to fund future operations without additional financing.
- Nasdaq Compliance: On March 17, 2025, the company received notice from Nasdaq that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive days. The company has a compliance period until September 15, 2025, to regain compliance.
- Preferred Stock Obligations: The company has significant obligations related to Series F, F-1, and G Preferred Stock, including monthly installment redemptions and dividends (10% annual, compounding monthly). Failure to meet these obligations could trigger default or require equity issuance, causing significant dilution.
- Cybersecurity: The company suffered a wire fraud incident in July 2023 resulting in a net loss of $78,198. While measures have been enhanced, the risk of future cyber-attacks remains a material risk.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $8.5M in cash and marketable securities against the burn rate and upcoming preferred stock redemption obligations.
- Dilution Risk: Review the full-ratchet anti-dilution provisions in the Series F, F-1, and G Preferred Stock and associated warrants, which have already triggered significant price adjustments (e.g., conversion prices adjusted to $0.364 in March 2025).
- Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq's $1.00 minimum bid price requirement by the September 15, 2025 deadline.
- Clinical Milestones: Confirm the initiation and progress of the Phase 2b Isomyosamine trial in Q1 2025, as this is a critical value driver.
- Related Party Transactions: Note that PharmaCyte Biotech, Inc. (controlled by Chairman Joshua Silverman) is a major investor in the Series G Preferred Stock and holds approximately 88.64% of the common stock.